Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 15,787 shares at $197.31 ($3.2M) on 2021-11-30, disclosed to the SEC on 2021-12-02.
Open-market sale of $3.2M NVAX by President, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $189.98 | 121 | $23K | 0.7% |
| 2 | $191.29 | 4 | $765 | 0.0% |
| 3 | $192.58 | 222 | $43K | 1.3% |
| 4 | $194.62 | 200 | $39K | 1.2% |
| 5 | $195.87 | 518 | $101K | 3.2% |
| 6 | $195.87 | 518 |
| $101K |
| 3.2% |
| 7 | $197.31 | 356 | $70K | 2.2% |
| 8 | $197.31 | 356 | $70K | 2.2% |
| 9 | $198.17 | 836 | $166K | 5.2% |
| 10 | $198.17 | 836 | $166K | 5.2% |
| 11 | $199.25 | 678 | $135K | 4.2% |
| 12 | $199.25 | 678 | $135K | 4.2% |
| 13 | $200.40 | 717 | $144K | 4.5% |
| 14 | $200.40 | 717 | $144K | 4.5% |
| 15 | $201.23 | 338 | $68K | 2.1% |
| 16 | $201.23 | 338 | $68K | 2.1% |
| 17 | $202.37 | 715 | $145K | 4.5% |
| 18 | $202.37 | 715 | $145K | 4.5% |
| 19 | $203.79 | 465 | $95K | 3.0% |
| 20 | $203.79 | 465 | $95K | 3.0% |
| 21 | $206.06 | 439 | $90K | 2.8% |
| 22 | $206.06 | 439 | $90K | 2.8% |
| 23 | $207.19 | 353 | $73K | 2.3% |
| 24 | $207.19 | 353 | $73K | 2.3% |
| 25 | $208.78 | 1,450 | $303K | 9.4% |
| 26 | $209.81 | 879 | $184K | 5.8% |
| 27 | $209.81 | 879 | $184K | 5.8% |
| 28 | $210.57 | 551 | $116K | 3.6% |
| 29 | $210.57 | 551 | $116K | 3.6% |
| 30 | $211.75 | 100 | $21K | 0.7% |
| Total | $202.99 avg | 15,787 | $3.2M | 100% |
| Filing → |
| NVAX | SELL | 2021-12-09 | $1.6M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |
| NVAX | SELL | 2021-11-24 | $2.5M | — | Filing → |